17 research outputs found
Ocular surface evaluation in patients treated with a fixed combination of prostaglandin analogues with 0.5% timolol maleate topical monotherapy: a randomized clinical trial
OBJECTIVES: To compare ocular surface changes induced via glaucoma treatment in patients using fixed combinations of prostaglandin analogues (travoprost, latanoprost and bimatoprost) with 0.5% timolol maleate METHODS: A prospective, multicenter, randomized, parallel group, single-blind clinical trial was performed in 33 patients with ocular hypertension or open angle glaucoma who had not been previously treated. The ocular surface was evaluated prior to and three months after treatment, with a daily drop instillation of one of the three medications. The main outcome measurements included the tear film break-up time, Schirmer's test, Lissamine green staining, the Ocular Surface Disease Index questionnaire, impression cytology using HE and PAS and immunocytochemistry for interleukin-6 and HLA-DR. Ensaiosclinicos.gov.br: UTN - U1111-1129-2872 RESULTS: All of the drugs induced a significant reduction in intraocular pressure. Decreases in the Schirmer's test results were observed with all of the drugs. Decreases in tear-film break-up time were noted with travoprost/timolol and latanoprost/timolol. An increase in the Lissamine green score was noted with travoprost/timolol and bimatoprost/timolol. The Ocular Surface Disease Index score increased after treatment in the travoprost/timolol group. Impression cytology revealed a significant difference in cell-to-cell contact in the same group, an increase in cellularity in all of the groups and an increase in the number of goblet cells in all of the groups. The fixed combinations induced an increase in IL-6 expression in the travoprost/timolol group, in which there was also an increase in HLA-DR expression. CONCLUSIONS: All of the fixed combinations induced a significant reduction in intraocular pressure, and the travoprost/timolol group showed increased expression of the inflammatory markers HLA-DR and interleukin-6. All three tested medications resulted in some degree of deterioration in the ocular surface after three months of glaucoma treatment.Federal University of Sao PauloFundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)Graefe Institute of Ophthalmology Glaucoma DepartmentFederal University of São Paulo CASO-Ocular Surface Advanced CenterBrasilia Base Hospital Glaucoma DepartmentFederal University of Parana Veterinary DepartmentFederal University of São Paulo OphthalmologyUNIFESP, CASO-Ocular Surface Advanced CenterUNIFESP, OphthalmologySciEL
Twelve-Month Follow-Up of Dexamethasone Implants for Macular Edema from Various Diseases in Vitrectomized and Nonvitrectomized Eyes
Purpose. To evaluate the best-corrected visual acuity (BCVA), central retinal thickness (CRT), and the number of dexamethasone implants needed to treat cystoid macular edema (CME) from various etiologies over 12 months in vitrectomized and nonvitrectomized eyes. Methods. This multicenter retrospective cohort study included 112 patients with CME secondary to retinal diseases treated pro re nata (PRN) with a 0.7 mg intravitreal dexamethasone implant for 12 months. The BCVA, CRT, adverse events, safety data, and number of implants were recorded. Results. Vitrectomized and nonvitrectomized eyes received means of three implants and one implant, respectively, over 12 months (P<0.001). The mean BCVA of all patients improved from 0.13 at baseline to 0.33 (P<0.001) 12 months after one (P=0.001), two (P=0.041), and three (P<0.001) implants but not four implants (P=0.068). The mean baseline CRT decreased significantly (P<0.001) from 463 to 254 microns after 12 months with one (P<0.001), two (P=0.002), and three (P=0.001) implants but not with four implants (P=0.114). The anatomic and functional outcomes were not significantly different between vitrectomized and nonvitrectomized eyes. Increased IOP was the most common adverse event (23.2%). Conclusions. Dexamethasone implant administered PRN improved VA and decreased CRT in CME, with possible long-term clinically relevant benefits for treating CME from various etiologies. Vitrectomized eyes needed more implants compared with nonvitrectomized eyes
Pervasive gaps in Amazonian ecological research
Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear un derstanding of how ecological communities respond to environmental change across time and space.3,4
While the increasing availability of global databases on ecological communities has advanced our knowledge
of biodiversity sensitivity to environmental changes,5–7 vast areas of the tropics remain understudied.8–11 In
the American tropics, Amazonia stands out as the world’s most diverse rainforest and the primary source of
Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepre sented in biodiversity databases.13–15 To worsen this situation, human-induced modifications16,17 may elim inate pieces of the Amazon’s biodiversity puzzle before we can use them to understand how ecological com munities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus
crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced
environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple or ganism groups in a machine learning model framework to map the research probability across the Brazilian
Amazonia, while identifying the region’s vulnerability to environmental change. 15%–18% of the most ne glected areas in ecological research are expected to experience severe climate or land use changes by
2050. This means that unless we take immediate action, we will not be able to establish their current status,
much less monitor how it is changing and what is being lostinfo:eu-repo/semantics/publishedVersio
A workshop on asthma management programs and centers in Brazil: reviewing and explaining concepts
Pervasive gaps in Amazonian ecological research
Biodiversity loss is one of the main challenges of our time,1,2 and attempts to address it require a clear understanding of how ecological communities respond to environmental change across time and space.3,4 While the increasing availability of global databases on ecological communities has advanced our knowledge of biodiversity sensitivity to environmental changes,5,6,7 vast areas of the tropics remain understudied.8,9,10,11 In the American tropics, Amazonia stands out as the world's most diverse rainforest and the primary source of Neotropical biodiversity,12 but it remains among the least known forests in America and is often underrepresented in biodiversity databases.13,14,15 To worsen this situation, human-induced modifications16,17 may eliminate pieces of the Amazon's biodiversity puzzle before we can use them to understand how ecological communities are responding. To increase generalization and applicability of biodiversity knowledge,18,19 it is thus crucial to reduce biases in ecological research, particularly in regions projected to face the most pronounced environmental changes. We integrate ecological community metadata of 7,694 sampling sites for multiple organism groups in a machine learning model framework to map the research probability across the Brazilian Amazonia, while identifying the region's vulnerability to environmental change. 15%–18% of the most neglected areas in ecological research are expected to experience severe climate or land use changes by 2050. This means that unless we take immediate action, we will not be able to establish their current status, much less monitor how it is changing and what is being lost
Development of implantation surgical technique and evaluation of security and biocompatibiliy of an intravitreal triamcinolone acetonide controlled release system in rabbits
Objetivo: Desenvolver a tecnica cirurgica de implantacao de um novo sistema intravitreo de liberacao controlada de triancinolona acetonida, bem como avaliar sua seguranca e biocompatibilidade em coelhos. Materiais e metodos: Um sistema de liberacao controlada de triancinolona acetonida para a cavidade vitrea foi desenvolvido e implantado cirurgicamente na cavidade vitrea de 40 coelhos. Foram utilizados implantes com diferentes velocidades de difusao: Grupo A (n=15) com lenta velocidade de difusao (1-2 μg/dia) e grupo B (n=15) com rapida velocidade de difusao (3-5 μg/dia). Alem destes, um grupo controle C (n=10) sem o medicamento tambem foi estudado. Os animais foram acompanhados por seis meses, sendo realizada inspecao geral, ectoscopia, afericao da pressao intra-ocular, mapeamento de retina com oftalmoscopia binocular indireta e histologia. Resultados: O sistema foi implantado com sucesso em todos os animais. Trinta e oito dos 40 animais completaram o estudo e os exames oftalmologicos revelaram como complicacoes cirurgicas o toque na capsula posterior do cristalino (14,4%), presenca de tecido pigmentado na extremidade intra-ocular do implante (30%) e hemorragia vitrea (22,5%). Durante os seis meses de acompanhamento pos-operatorio foi observada preservacao da superficie ocular e 66,6% dos animais desenvolveram algum tipo de opacidade de cristalino. Nao foram observadas alteracoes de pressao intra-ocular entre os grupos. Analise histologica revelou ausencia de alteracoes. Conclusao: O procedimento cirurgico de implantacao do sistema de liberacao controlada de triancinolona acetonida em coelhos demonstrouse factivel, reprodutivel e sujeito a complicacoes previsiveis. O acompanhamento durante o periodo pos-operatorio de seis meses revelou boa biocompatibilidadeBV UNIFESP: Teses e dissertaçõe